CRISPR Therapeutics AG (CRSP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 70M 140M 210M Q3 '21: 824K Q4 '21: 12.9M Q1 '22: 940K Q2 '22: 158K Q3 '22: 94K Q4 '22: 6K Q1 '23: 100M Q2 '23: 70M Q3 '23: 0 Q4 '23: 201.2M Q1 '24: 504K Q2 '24: 517K Q3 '24: 602K Q4 '24: 35.7M Q1 '25: 865K Q2 '25: 892K Q3 '25: 889K Q4 '25: 864K Q1 '26: 1.5M Q2 '26: 10.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-240M -160M -80M 0 80M 160M 240M Q3 '21: -128.8M Q4 '21: -145.7M Q1 '22: -176M Q2 '22: -183.3M Q3 '22: -182.4M Q4 '22: -131.5M Q1 '23: -64.5M Q2 '23: -95.2M Q3 '23: -132.4M Q4 '23: 69.6M Q1 '24: -140.6M Q2 '24: -151.3M Q3 '24: -110.1M Q4 '24: -64.6M Q1 '25: -148.4M Q2 '25: -229.3M Q3 '25: -132.1M Q4 '25: -154.8M Q1 '26: -130.2M Q2 '26: -117.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-240M -160M -80M 0 80M 160M 240M Q3 '21: -127.2M Q4 '21: -141.2M Q1 '22: -179.2M Q2 '22: -185.8M Q3 '22: -174.5M Q4 '22: -110.6M Q1 '23: -53.1M Q2 '23: -77.7M Q3 '23: -112.2M Q4 '23: 89.3M Q1 '24: -116.6M Q2 '24: -126.4M Q3 '24: -85.9M Q4 '24: -37.3M Q1 '25: -136M Q2 '25: -208.5M Q3 '25: -106.4M Q4 '25: -130.6M Q1 '26: -122.9M Q2 '26: -91.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '21: -81.3M Q4 '21: -86M Q1 '22: -135.2M Q2 '22: -142M Q3 '22: -105.2M Q4 '22: -113.3M Q1 '23: 8.8M Q2 '23: -133.2M Q3 '23: -39.9M Q4 '23: -96.1M Q1 '24: 109.8M Q2 '24: -95.6M Q3 '24: -106.9M Q4 '24: -50M Q1 '25: -53.9M Q2 '25: -113.9M Q3 '25: -84.6M Q4 '25: -92.6M Q1 '26: -108.9M Q2 '26: -83.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-180M -120M -60M 0 60M 120M 180M Q3 '21: -118.4M Q4 '21: -95.2M Q1 '22: -150.6M Q2 '22: -151.6M Q3 '22: -111.2M Q4 '22: -119.5M Q1 '23: 5.7M Q2 '23: -136.8M Q3 '23: -42M Q4 '23: -96.8M Q1 '24: 109M Q2 '24: -96.3M Q3 '24: -107.1M Q4 '24: -50.3M Q1 '25: -54.2M Q2 '25: -114M Q3 '25: -84.7M Q4 '25: -93.1M Q1 '26: -109.4M Q2 '26: -84.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q2 '20: 61.4M Q3 '20: 70.1M Q4 '20: 71.3M Q1 '21: 75M Q2 '21: 80.4M Q3 '21: 76.3M Q1 '22: 77.1M Q2 '22: 77.5M Q3 '22: 78M Q1 '23: 78.7M Q2 '23: 79.1M Q3 '23: 79.4M Q1 '24: 81.8M Q2 '24: 84.9M Q3 '24: 85.2M Q1 '25: 85.9M Q2 '25: 87.1M Q3 '25: 91.3M Q1 '26: 96.1M Q2 '26: 96.5M Q3 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-9.00 -6.00 -3.00 0.00 3.00 6.00 9.00 Q3 '21: 4.76 Q4 '21: 4.70 Q1 '22: 3.89 Q2 '22: -7.95 Q3 '22: -8.52 Q4 '22: -8.36 Q1 '23: -6.71 Q2 '23: -5.29 Q3 '23: -4.46 Q4 '23: -1.94 Q1 '24: -2.70 Q2 '24: -3.21 Q3 '24: -2.81 Q4 '24: -4.35 Q1 '25: -4.50 Q2 '25: -5.41 Q3 '25: -5.57 Q4 '25: -6.50 Q1 '26: -6.20 Q2 '26: -4.74 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.